Avidity Biosciences, Inc. (RNA) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 2, 2026, Avidity Biosciences, Inc. (RNA) trades at a price-to-earnings ratio of -3.0x, with a stock price of $14.75 and trailing twelve-month earnings per share of $-4.97.
Compared to the Healthcare sector median P/E of 23.7x, RNA trades at a 113% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, RNA trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RNA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. RNA and Genome Editing Developers peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
ALNYAlnylam Pharmaceuticals, Inc. | $44B | 142.9 | -Best | +207% |
SLXNWSilexion Therapeutics Ltd. | $64M | 0.0Lowest | -Best | +6436%Best |
DTILPrecision BioSciences, Inc. | $51M | 4.0 | -Best | +107% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See RNA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RNA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare RNA vs AGIO
See how RNA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is RNA stock overvalued or undervalued?
RNA current P/E: -3.0x. 5-year average P/E: N/A. Percentile: N/A.
How does RNA's valuation compare to peers?
Avidity Biosciences, Inc. P/E of -3.0x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is RNA's PEG ratio?
RNA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.